Sarah Atkinson
General Practice · Rochester, NYNPI 1285859306
Payments from drug & device makers
Across 575 payments — averaging $7270.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.3M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$791K
- Sunovion Pharmaceuticals Inc.$655K
- Supernus Pharmaceuticals, Inc.$291K
- Roche TCRC, Inc.$132K
- Takeda Pharmaceuticals U.S.A., Inc.$131K
- plus $884K from 18 others
Across 199 payments — averaging $4429.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$444K
- Acadia Pharmaceuticals Inc$370K
- Avanir Pharmaceuticals, Inc.$56K
- Takeda Pharmaceuticals U.S.A., Inc.$11K
What the payments were for
- Consulting fees$7,40072%
- Travel & lodging$1,90119%
- Food & beverage$9609%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 158 | $1,296,577 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 31 | $790,725 |
| Sunovion Pharmaceuticals Inc. | 81 | $654,842 |
| Supernus Pharmaceuticals, Inc. | 43 | $291,367 |
| Roche TCRC, Inc. | 22 | $131,819 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $131,159 |
| Pfizer | 47 | $129,430 |
| Boehringer Ingelheim | 11 | $129,031 |
| Biogen | 4 | $123,160 |
| Acadia Pharmaceuticals Inc | 20 | $110,534 |
| H. Lundbeck A S | 13 | $100,453 |
| Sage Therapeutics, LLC | 14 | $74,469 |
| Janssen Research & Development, LLC | 31 | $52,415 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $43,762 |
| Biohaven Pharmaceuticals, Inc. | 12 | $41,885 |
| Sumitomo Pharma America, Inc. | 2 | $30,702 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $11,147 |
| Avanir Pharmaceuticals, Inc. | 7 | $10,316 |
| Hoffmann-la Roche Limited | 1 | $7,500 |
| Alkermes, Inc. | 7 | $7,019 |
| Modernatx, Inc. | 1 | $6,000 |
| Neurocrine Biosciences, Inc. | 9 | $2,635 |
| Boehringer Ingelheim RCV GmbH & Co KG | 22 | $2,210 |
| F. Hoffmann-la Roche AG | 1 | $1,100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEODON$1,524
How this compares
$4,180,258 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 13 | $28,708 |
| TrintellixVortioxetine Hydrobromide | 14 | $13,782 |
| Paliperidone ErPaliperidone | 12 | $3,951 |
| Bupropion XlBupropion Hcl | 37 | $1,897 |
| Aripiprazole | 24 | $964 |
| Trazodone Hcl | 12 | $525 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $512 |
| Duloxetine Hcl | 26 | $360 |
| Bupropion Hcl SrBupropion Hcl | 20 | $335 |
| Clozapine | 13 | $309 |
| Buspirone Hcl | 16 | $279 |
| Lamotrigine | 13 | $253 |
| Sertraline Hcl | 29 | $218 |
| Lithium Carbonate ErLithium Carbonate | 16 | $150 |
| Clonazepam | 19 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $131,159 | $13,78214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,764 general practice providers in New York.
Other general practice in Rochester
- Frank LamarRochester$34K
- James LamarRochester$32K
- Joseph DidonatoRochester$19K
- Mark HochmanHicksville$5.1M
- Michael MashaalRoslyn$1.9M
- David RiceEast Amherst$1.2M
- Alejandra Gonzalez-DuarteNew York$519K
- Brian JacksonUtica$477K
- Ronnie MyersNew York$464K
- Ira LangsteinWhite Plains$422K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.